TMBR

Timber Pharmaceuticals Stock Price

2.11
-0.02 (-0.94%)
Upgrade to Real-Time
Afterhours (Closed)
2.11
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Timber Pharmaceuticals Inc TMBR AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.94% 2.11 19:59:32
Open Price Low Price High Price Close Price Prev Close
2.09 2.07 2.23 2.12 2.13
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,372 1,792,519 $ 2.15 $ 3,849,036 6,737,206 0.6651 - 4.17
Last Trade Time Type Quantity Stock Price Currency
20:00:00 6,200 $ 2.12 USD

Timber Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 25.00M 11.85M 11.85M $ 270.54k $ - -0.26 -0.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Timber Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TMBR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.282.301.952.132,107,395-0.17-7.46%
1 Month2.583.041.672.317,582,973-0.47-18.22%
3 Months1.073.650.922.3610,226,3271.0497.2%
6 Months1.103.650.66512.036,144,6351.0191.82%
1 Year4.114.170.66512.033,760,573-2.00-48.66%
3 Years4.114.170.66512.033,760,573-2.00-48.66%
5 Years4.114.170.66512.033,760,573-2.00-48.66%

Timber Pharmaceuticals Description

Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma. Its development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist).


Your Recent History
AMEX
TMBR
Timber Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.